Furthermore, this study underscores the importance of identifying patients who may benefit from novel HER2-targeted therapies, such as T-DXd, by implementing comprehensive and routine ERBB2/HER2 testing, even in tumor types where such approval is not standard practice. The gene discussed is ERBB2; the disease is neoplasm.